Medicine is moving from chemistry to code
For a century, medicine was built from chemistry. RNA and DNA medicines work differently, reading, understanding and responding to disease at the molecular level.
For a century, medicine was built from chemistry, small molecules that treat the symptoms of disease. RNA and DNA medicines work differently. They read, understand and respond to disease at the molecular level, addressing its cause rather than its effect.
This is no longer a promise. RNA interference medicines, antisense oligonucleotides, mRNA vaccines and CRISPR gene editing are already approved and in patients, reaching diseases that were considered untreatable only a decade ago. The field has been recognised with three Nobel Prizes in under two decades: RNA interference in 2006, CRISPR gene editing in 2020, and mRNA vaccine technology in 2023.
The bottleneck is no longer the science. It is the speed of discovery and access to validated, regulated material to move programs forward. Syngenis was built to solve both, bringing AI led discovery, our own laboratories and clinical delivery under one roof.
Bring your program to Syngenis
Talk to our team about your program, from candidate design to trial ready material.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.